What are the potential side effects of spironolactone?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Side Effects of Spironolactone

Spironolactone commonly causes electrolyte disturbances (particularly hyperkalemia), menstrual irregularities, breast-related effects, and various other side effects that require monitoring but are generally manageable with appropriate dosing and follow-up. 1

Common Side Effects

Endocrine and Reproductive Effects

  • Menstrual irregularities: Occurs in 15-30% of women, with risk increasing significantly at higher doses (relative risk of 4.12 for women taking 200mg/day compared to lower doses) 2
  • Breast tenderness: 3-5% of patients 2
  • Gynecomastia: More common in men, reported in 1.8% of patients in a cardiology practice 3
  • Decreased libido and erectile dysfunction 1
  • Postmenopausal bleeding 1

Electrolyte and Metabolic Abnormalities

  • Hyperkalemia: Most potentially dangerous side effect, occurring in approximately 5.3% of patients 3
  • Hyponatremia and hypovolemia 1
  • Diuresis: Reported in 29% of patients 2
  • Polyuria: 1-2% of patients 2

Gastrointestinal Effects

  • Nausea: 2-4% of patients 2
  • Gastritis: Reported in 2% of patients in a cardiology practice 3
  • Diarrhea, cramping, vomiting, gastric bleeding, and ulceration 1

Neurological Effects

  • Dizziness: 3-4% of patients 2
  • Lethargy, mental confusion, headache, drowsiness 1
  • Impaired neurological function/coma: Particularly in patients with hepatic impairment 1

Dermatologic Effects

  • Skin rashes: Including Stevens-Johnson Syndrome, toxic epidermal necrolysis, and DRESS syndrome (rare but serious) 1
  • Alopecia and pruritus 1
  • "Chloasma": Facial pigmentation (rare) 4

Hematologic Effects

  • Leukopenia (including agranulocytosis)
  • Thrombocytopenia 1

Risk Factors and Monitoring

High-Risk Populations

  • Elderly patients: More likely to have decreased renal function, increasing risk of adverse effects 1
  • Patients with renal impairment: At increased risk of hyperkalemia 1
  • Patients with hepatic impairment: Risk of sudden fluid/electrolyte alterations that may precipitate hepatic encephalopathy 1
  • Patients taking other medications affecting potassium levels 2

Monitoring Recommendations

  • Potassium monitoring: Recommended for older patients, those with medical comorbidities, and patients taking medications affecting potassium levels 2
  • Renal function: Should be assessed prior to initiating therapy and monitored periodically 1
  • Side effect assessment: Regular review during the initial 3 months of treatment is advised as side effects tend to occur early 4

Management Strategies

Dosing Considerations

  • Start low: Begin with lower doses (25-50mg daily) to minimize side effects 5
  • Cyclic administration: Consider administering 50mg twice daily on days 4-21 of the menstrual cycle to reduce menstrual irregularities 6
  • Dose adjustment: If side effects occur, reducing the dose may achieve a compromise between controlling the disease and managing side effects 4

Combination Therapies

  • Combined oral contraceptives: Highly effective in regulating menstrual cycles while on spironolactone 2
  • Hormonal intrauterine devices: Can help minimize menstrual irregularities 2

Dietary Considerations

  • Avoid high-potassium diets to reduce risk of hyperkalemia 2

Special Considerations

Pregnancy and Breastfeeding

  • Pregnancy: Spironolactone is pregnancy category C and should not be used during pregnancy due to potential feminization of male fetuses 2
  • Breastfeeding: Limited data suggests low amounts of the active metabolite in breast milk, with no adverse effects reported after short-term exposure 1

Long-term Safety

  • Studies following patients for up to 8 years have not shown serious adverse effects with long-term use 2
  • No increased risk of breast, ovarian, bladder, kidney, gastric, or esophageal cancer with spironolactone use 2

References

Guideline

Hair Loss Treatment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Tolerance of spironolactone.

The British journal of dermatology, 1988

Research

Side-effects of spironolactone therapy in the hirsute woman.

The Journal of clinical endocrinology and metabolism, 1988

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.